About ReNeuron (OTCMKTS:RNUGF)
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Industry, Sector and Symbol
Industry Private households
Trailing P/E Ratio-1.22
Forward P/E Ratio-1.24
Sales & Book Value
Price / Sales643.55
Price / CashN/A
Book Value$2.20 per share
Price / Book0.55
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
ReNeuron (OTCMKTS:RNUGF) Frequently Asked Questions
What is ReNeuron's stock symbol?
ReNeuron trades on the OTCMKTS under the ticker symbol "RNUGF."
When is ReNeuron's next earnings date?
Who are some of ReNeuron's key competitors?
Some companies that are related to ReNeuron include Bovie Medical (BVX), Xenon Pharmaceuticals (XENE), aTyr Pharma (LIFE), Immunodiagnostic Systems Hld (IDH), Genocea Biosciences (GNCA), vTv Therapeutics (VTVT), Fulgent Genetics (FLGT), Eleven Biotherapeutics (EBIO), Regulus Therapeutics (RGLS), Edap Tms (EDAP), Vascular Biogenics (VBLT), Brainstorm Cell Therapeutics (BCLI), Axsome Therapeutics (AXSM), Sophiris Bio (SPHS), Navidea Biopharmaceuticals (NAVB), Obalon Therapeutics (OBLN), Five Star Senior Living (FVE) and Arcturus Therapeutics (ARCT).
Who are ReNeuron's key executives?
ReNeuron's management team includes the folowing people:
- Mr. Olav Hellebø, Chief Exec. Officer and Director (Age 53)
- Mr. Michael E. Hunt BSc, ACA, CFO, Sec. & Exec. Director (Age 55)
- Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 67)
- Dr. Randolph Corteling Ph.D., Head of Research
- Ms. Sharon Grimster FSB, AFIChemE, BSc, DMS, VP of Devel. & GM of Wales (Age 59)
Has ReNeuron been receiving favorable news coverage?
Press coverage about RNUGF stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ReNeuron earned a coverage optimism score of 0.09 on Accern's scale. They also assigned news stories about the company an impact score of 44.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of ReNeuron?
Shares of RNUGF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ReNeuron's stock price today?
One share of RNUGF stock can currently be purchased for approximately $1.22.
How big of a company is ReNeuron?
ReNeuron has a market capitalization of $38.61 million and generates $60,000.00 in revenue each year. The company earns $-20,350,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.
How can I contact ReNeuron?
ReNeuron's mailing address is Pencoed Business Park Bridgend, Pencoed X0, CF35 5HY. The company can be reached via phone at 44-20-3819-8400.
MarketBeat Community Rating for ReNeuron (RNUGF)MarketBeat's community ratings are surveys of what our community members think about ReNeuron and other stocks. Vote "Outperform" if you believe RNUGF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNUGF will underperform the S&P 500 over the long term. You may vote once every thirty days.
ReNeuron (OTCMKTS:RNUGF) Analyst Ratings History
(Data available from 4/21/2016 forward)
ReNeuron (OTCMKTS:RNUGF) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
ReNeuron (OTCMKTS RNUGF) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 0.08%
ReNeuron (OTCMKTS RNUGF) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
ReNeuron (OTCMKTS RNUGF) News Headlines
ReNeuron (OTCMKTS:RNUGF) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
ReNeuron (OTCMKTS RNUGF) Stock Chart for Saturday, April, 21, 2018